Millipore Sigma Vibrant Logo

616464 InSolution™ TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9 - Calbiochem

View This Product on Sigma-Aldrich
616464
価格&在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
301836-41-9C₂₂H₁₆N₄O₃ • 2H₂O

価格&在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
616464-5MGCN
在庫状況検索中…
現在国内在庫なし
現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      ガラスビン 5 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示 
      値引
      ()
       
      弊社照会
      Description
      OverviewA cell-permeable triarylimidazole compound that is shown to effectively inhibit cellular Smad2 phosphorylation (>90% inhibition by 10 µM inhibitor) upon vector-mediated expression of constitutively active ALK4, ALK5, or ALK7 in NIH 3T3 cells, while exhibiting little effect against Smad1 phosphorylation by other members of type I receptors for TGF-β in NIH 3T3 cultures expressing active ALK1, 2, 3, or 6. When tested directly in cell-free kinase assays, SB431542 is demonstrated to potently inhibit the activity of ALK4 and ALK5 (IC50 = 140 nM and 94 nM, respectively) with no or much reduced potency toward a panel of 24 other kinases (IC50 ≥10 µM in the presence of 10 µM ATP), including ALK2 and ALK6. Reported to improve the efficiency of 4-TF-induced human iPSCs generation from fibroblast cultures by >200-fold when used together with PD0325901 (Cat. No. 444966) and Thiazovivin (Cat. No. 420220). The solid form of this compound (Cat. No. 616461) is also available.
      Catalogue Number616464
      Brand Family Calbiochem®
      References
      ReferencesIkushima, H., et al. 2009. Cell Stem Cell 5, 504.
      Lin, T., et al. 2009. Nat. Methods 6, 805.
      Maherali, N. and Hochedlinger, K., 2009. Curr. Biol. 19, 1718.
      Callahan, J.F., et al. 2002. J. Med. Chem. 45, 999.
      Inman, G.J., et al. 2002. Mol. Pharmacol. 62, 65.
      Laping, N.J., et al. 2002. Mol. Pharmacol. 62, 58.
      Product Information
      CAS number301836-41-9
      FormLiquid
      FormulationA 100 mM (5 mg/119 µl) solution of SB431542 (Cat. No. 616461) in DMSO.
      Hill FormulaC₂₂H₁₆N₄O₃ • 2H₂O
      Chemical formulaC₂₂H₁₆N₄O₃ • 2H₂O
      Hygroscopic Hygroscopic
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      ApplicationInSolution™ TGF-β RI Kinase Inhibitor VI, SB431542, CAS 301836-41-9, is a 100 mM solution in DMSO.A cell-permeable, selective inhibitor of SMAD2 phosphorylation (greater than 90% inhibition at 10 µM).
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 36/38

      Irritating to eyes and skin.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Irritant
      Storage -20°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      616464-5MGCN 04055977185942

      Documentation

      InSolution™ TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート((M)SDS) 

      InSolution™ TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9 - Calbiochem 試験成績書(CoA)

      タイトルロット番号
      616464

      参考資料

      参考資料の概要
      Ikushima, H., et al. 2009. Cell Stem Cell 5, 504.
      Lin, T., et al. 2009. Nat. Methods 6, 805.
      Maherali, N. and Hochedlinger, K., 2009. Curr. Biol. 19, 1718.
      Callahan, J.F., et al. 2002. J. Med. Chem. 45, 999.
      Inman, G.J., et al. 2002. Mol. Pharmacol. 62, 65.
      Laping, N.J., et al. 2002. Mol. Pharmacol. 62, 58.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision01-February-2012 RFH
      DescriptionA cell-permeable triarylimidazole compound that is shown to effectively inhibit cellular Smad2 phosphorylation (>90% inhibition by 10 µM inhibitor) upon vector-mediated expression of constitutively active ALK4, ALK5, or ALK7 in NIH 3T3 cells, while exhibiting little effect against Smad1 phosphorylation by other members of type I receptors for TGF-β in NIH 3T3 cultures expressing active ALK1, 2, 3, or 6. When tested directly in cell-free kinase assays, SB431542 is demonstrated to potently inhibit the activity of ALK4 and ALK5 (IC50 = 140 nM and 94 nM, respectively) with no or much reduced potency toward a panel of 24 other kinases (IC50 ≥10 µM in the presence of 10 µM ATP), including ALK2 and ALK6. Reported to improve the efficiency of 4-TF-induced human iPSCs generation from fibroblast cultures by >200-fold when used together with PD0325901 (Cat. No. 444966) and Thiazovivin (Cat. No. 420220).
      FormLiquid
      FormulationA 100 mM (5 mg/119 µl) solution of SB431542 (Cat. No. 616461) in DMSO.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number301836-41-9
      Chemical formulaC₂₂H₁₆N₄O₃ • 2H₂O
      Structure formulaStructure formula
      Purity≥97% by HPLC
      Storage Protect from light
      -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Toxicity Irritant
      ReferencesIkushima, H., et al. 2009. Cell Stem Cell 5, 504.
      Lin, T., et al. 2009. Nat. Methods 6, 805.
      Maherali, N. and Hochedlinger, K., 2009. Curr. Biol. 19, 1718.
      Callahan, J.F., et al. 2002. J. Med. Chem. 45, 999.
      Inman, G.J., et al. 2002. Mol. Pharmacol. 62, 65.
      Laping, N.J., et al. 2002. Mol. Pharmacol. 62, 58.